Latest From Biotech Now

BIO’s Next Generation Partnering System to Open April 2015

partnering-HP-300x312

You’ve found your lead investor. Now it’s time to get to the next stage, and the best place to do so is the 2015 BIO International Convention. You have a meeting with Pfizer at 9:00 a.m. followed by a meeting with AstraZeneca/MedImmune at 9:30 a.m. Then a 30 minute break. Then you have four meetings back to back with Sofinnova, Takeda Ventures, Gates Foundation and Merck. After a quick lunch it’s back to partnering: make Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

Agricultural Coexistence: We All Can Get Along

James Brewbaker

On March 12-13, 2015, The U.S. Department of Agriculture (USDA) will be holding a Stakeholder Workshop on Coexistence to advance the understanding of agricultural coexistence. Coexistence is not a safety issue. Agricultural Coexistence is the practice of concurrent cultivation of conventional, organic, identity preserved (IP), and genetically engineered (GE) crops consistent with underlying consumer preferences and farmer choices. The Workshop will discuss opportunities for making coexistence more achievable and a basic consideration for all stakeholders. It Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Consumer Reports Does Consumers No Favors

Consumer_Reports

Like most people, I enjoy Consumer Reports for their ability to provide fact-based product reviews when I’m shopping for a new toaster or a computer or a car.  So it’s disheartening to learn that Consumer Reports‘ advice isn’t always fact-based. Take, for example, their recent article “GMO foods: What you need to know.”  I wish the title of this was “GMO foods: What Consumers Union wants you to believe.”  Consumers Union – as noted in Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

We Need Your Input: BIO Survey on Effective FDA-Sponsor Communication

FDA115x76

BIO is surveying members and non-members on their interactions with the FDA during the various stages of drug development prior to submitting an NDA/BLA. The survey can be accessed here. Why is it important for you to share your feedback? In an increasingly competitive and fiscally-constrained environment, it is more important than ever for all stakeholders to work together to promote effective R&D for innovative medicines. In this BIO BuzzCenter video, Alnylam’s Dr. John Maraganore Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

The Perfect Close

72263479

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,